Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2018

View Archived Issues

Adipose-derived regenerative cell therapy safe in patients with erectile dysfunction

Polymorphisms in miRNA-146a and IRAK1 are associated with susceptibility to SLE and MS

Harbour BioMed licenses ex-China rights to Kelun-Biotech's A-167

Common pathway may underlie schizophrenia and PD

Getting at stored mRNAs part of fragile X problem

HDAC inhibitors optimized for CNS drug-like properties and hematological safety

Phase Ib data guide Novan's development of SB-414 for atopic dermatitis

New oral selective apelin agonist AM-2995 developed for heart disease treatment

Chugai's describes candidate for the treatment of hyperphosphatemia EOS-798

Novo Nordisk reports topline PIONEER 5 results for oral semaglutide

Phase III study of MC2-01 cream in psoriasis vulgaris meets primary and secondary endpoints

Biogen identifies new NRF2 activators

Adare Pharmaceuticals describes cysteamine prodrugs

Antiangiogenic compounds synthesized at Celgene

Vectura completes pediatric studies with VR-647 for asthma

Hanmi Science patents oncolytic compounds

New Rho kinase inhibitors described by Chiesi Farmaceutici

Japanese approval for Tagrisso as first-line treatment of EGFR-mutated NSCLC

Phase II trial of TLC-599 for osteoarthritis pain meets primary and key secondary endpoints

FDA approves expanded label for Keytruda for first-line treatment of metastatic non-squamous NSCLC

Ascentage Pharma opens phase I trial of APG-2575 in hematologic malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...